{
    "nct_id": "NCT04384848",
    "official_title": "Evaluating Patient-Reported Outcomes Monitoring in Routine Care of Patients With Chronic Myeloid Leukemia for Increasing Adherence and Clinical Response to THerapY: The EMPATHY Pilot Study",
    "inclusion_criteria": "1. Diagnosis of Philadelphia chromosome positive and/or BCR-ABL positive CML confirmed by cytogenetic and/or molecular analysis;\n2. Newly diagnosed chronic phase (CP)-CML Patients planned to receive one of the following TKI approved as first line treatment: imatinib, dasatinib, nilotinib or bosutinib;\n3. Adult Patients (â‰¥18 years) at the time of study entry; Children under the age of 18 will be excluded from the study. The exclusion of children is justified by the following circumstances: a) The condition is relatively rare in children, as compared to adults; b) Issues of study preclude direct applicability of hypotheses and/or interventions to both adults and children.\n4. Written informed consent.\n5. Written informed consent from Patient's physician as a participant.\n6. Newly diagnosed Chronic Phase (CP)-CML Patients who are within 4 weeks of first line TKI therapy (anyone of the TKI approved in the USA and Europe, that is: imatinib, dasatinib, nilotinib or bosutinib).\n7. Ability to read/converse in English (Northwestern University and Augusta University Sites). Ability to read/converse in Italian (GIMEMA Centers).\n\nPatient exclusion criteria will include:\n\n1. Major cognitive deficits or psychiatric problems hampering a self-reported evaluation;\n2. Having received any CML treatment - other than TKI - for more than 3 months prior to receiving current TKI therapy.\n\nThis project will focus on CML, which affect both men and women. Therefore, there are no exclusion/inclusion criteria based on sex/gender. In addition, there are no exclusion/inclusion criteria based on race and ethnicity.\n\nPhysician inclusion criteria will include:\n\n1)Provider of clinical care for Patient who meets inclusion criteria for the study\n\nPlease note that Physician consent is requisite for the Patient to be enrolled as a participant in the study.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Major cognitive deficits or psychiatric problems hampering a self-reported evaluation\n2. Having received any CML treatment prior to therapy with imatinib, dasatinib, bosutinib or nilotinib for more than three months",
    "miscellaneous_criteria": ""
}